The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals ... complete response letter for the drug, etripamil, indicating the agency won't approve ...

The letter did not raise any concerns regarding clinical safety or efficacy data. The Food and Drug Administration (FDA) has issued a Complete Response Letter to Milestone Pharmaceuticals ...

Milestone Pharmaceuticals MIST recently announced that the FDA has issued a Complete Response Letter (“CRL”) for its New Drug ...

Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...

Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and ...

after the company announced receipt of a complete response letter from the FDA regarding its new drug application for its etripamil nasal spray for the treatment of paroxysmal supraventricular ...

Milestone Pharmaceuticals shares collapsed on Friday after the U.S. Food and Drug Administration once again turned away the biopharmaceutical company's proposed etripamil nasal spray to treat a ...

Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and ...